The Human Tumor Atlas Network leverages scientific collaboration to integrate samples, analytical modalities and tools into detailed atlases of tumor evolution. Expanding our spatial understanding ...

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B ...

Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data ...